 - Patients with any of the following hepatic conditions prior to study: a history of chronic liver or biliary disease, b total conjugated bilirubin greater than 1.5 times upper limits of normal ULN range, unless in the context of Gilberts syndrome, c alkaline phosphatase greater than 1.5 times the ULN range, d aspartate transaminase AST, alanine transaminase ALT greater than 3 times the ULN if the elevation of AST or ALT, according to the investigator, is attributable to liver disease. Patients with elevated ASTALT due to myositis disease activity are eligible, e Gamma-glutamyltransferase GGT greater than 3 times the ULN range 